Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  regorafenib
Find trials that include:  Any drugs shown
Results 1-25 of 27 for your search:
Start Over
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 15982, NCI-2013-01156, 2012-003649-14, NCT01774344
DNA Methyltransferase Inhibitor SGI-110 and Irinotecan Hydrochloride or Regorafenib Alone in Treating Patients with Previously Treated Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NA_00085870, J1369, NCI-2013-02005, CIR00004735, CIR0002117, NA_00085870, NCT01896856
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 17064, NCI-2014-01527, 2013-004861-15, NCT02168777
Combination Chemotherapy with or without Regorafenib in Treating Patients with Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1029, NCI-2013-00954, 10-2176, NCT01298570
Regorafenib in Treating Patients with Newly Diagnosed Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-211, NCI-2014-00002, NCT02023333
A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC024, NCI-2014-02023, NCT02048371
Regorafenib in Treating Patients with Previously Treated, Metastatic, or Locally Advanced Angiosarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 13S02, NCI-2013-02278, ONC-2013-129, STU00087654, NCT02048722
Regorafenib in Treating Patients With Advanced or Metastatic Biliary Tract Cancer Who Failed First-Line Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 13-100, NCI-2014-01117, NCT02053376
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-21-02, NCI-2014-00908, NCT02096354
Regorafenib in Treating Patients with Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-244, NCI-2014-00776, NCT02098538
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17651, NCI-2014-00956, 14.02.0015, NCT02115542
Study of Ruxolitinib in Colorectal Cancer Patients
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB18424-267, NCI-2014-01443, NCT02119676
Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RU021212I, NCI-2014-01962, NCT02234180
Regorafenib in Treating Patients with Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HCI77685, NCI-2015-00550, 77685, NCT02278783
Regorafenib in Reducing Recurrence in Patients with Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 246813, NCI-2014-02202, BAY ONC-3012-036, ONC-2013-036, NCT02287727
Vorinostat and Hydroxychloroquine or Regorafenib in Treating Patients with Refractory Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CTMS 14-2015, NCI-2015-00203, 14-2015, 2015, HSC20150178H, NCI-2015-00175, NCT02316340
Lower or Standard Dose Regorafenib in Treating Patients with Refractory Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RU021407I, NCI-2015-00011, Mod14-008756-03, NCT02368886
Regorafenib and Gemcitabine Hydrochloride as Second-Line Therapy in Treating Patients with Metastatic Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CASE5214, NCI-2015-00146, NCT02383433
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16547, NCI-2013-02227, NCT01973868
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
Regorafenib and Cetuximab in Treating Patients with Refractory or Relapsed Advanced Solid Tumor Malignancies
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0833, NCI-2014-01307, NCT02095054
Regorafenib and Anti-ALK-1 Monoclonal Antibody PF-03446962 in Treating Patients with Refractory Metastatic Colorectal Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00051541, NCI-2014-01945, NCT02116894
Panitumumab and Regorafenib in Treating Patients with Advanced or Metastatic KRAS or NRAS Wild Type Colorectal Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HCI72561, NCI-2014-01825, NCT02199223
Start Over